^
No biomarker
Chordoma
sorafenib
Sensitive: A2 - Guideline
No biomarker
Chordoma
dasatinib
Sensitive: A2 - Guideline
No biomarker
Chordoma
YD312
Sensitive: A2 - Guideline
No biomarker
Chordoma
sunitinib
Sensitive: A2 - Guideline
No biomarker
Chordoma
erlotinib
Sensitive: A2 - Guideline
TMB-H
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
EGFR expression
Chordoma
lapatinib
Sensitive: A2 - Guideline
MSI-H/dMMR
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Chordoma
imatinib
Sensitive: A2 - Guideline
SMARCB1 negative
Chordoma
tazemetostat
Sensitive: C2 – Inclusion Criteria
PIK3CA amplification
Chordoma
everolimus
Sensitive: C3 – Early Trials
PIK3CA M1043I
Chordoma
everolimus
Sensitive: C3 – Early Trials
PTEN deletion
Chordoma
PDGFR inhibitor
Resistant: C4 – Case Studies
PTEN deletion
Chordoma
PDGFR inhibitor + HDAC inhibitor
Sensitive: C4 – Case Studies
AXL underexpression
Chordoma
afatinib
Sensitive: D – Preclinical
STK33 underexpression
Chordoma
afatinib
Sensitive: D – Preclinical